NovaBridge Biosciences
0VY
Company Profile
Business description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
30
Stocks News & Analysis
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,313.20 | 19.60 | -0.21% |
| CAC 40 | 8,636.80 | 13.76 | -0.16% |
| DAX 40 | 26,440.31 | 140.57 | 0.53% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,750.11 | 22.56 | -0.21% |
| HKSE | 25,116.85 | 279.66 | -1.10% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 68,713.80 | 405.20 | 0.59% |
| NZX 50 Index | 13,854.38 | 29.08 | 0.21% |
| S&P 500 | 7,785.76 | 13.23 | -0.17% |
| S&P/ASX 200 | 9,115.20 | 19.90 | -0.22% |
| SSE Composite Index | 3,927.18 | 0.21 | 0.01% |